论文部分内容阅读
“维C案”中商务部三封“法庭之友”意见书最终被二审法院采纳,以国际礼让原则胜诉。然而此胜利无法掩盖我国出口卡特尔豁免制度立法欠缺、商会预警能力不足、企业规避风险意识淡薄等现实问题。2016年9月20日,美国联邦第二巡回上诉法院作出了关于华北制药对“维生素C反垄断诉讼案”上诉的判决,支持华北制药在一审中被驳回的被告动议,以国际礼让原则判决一审判决无效,中方胜诉。至此,这场旷日持久,被称为“中国国际反垄断诉讼第一案”的官司终于尘埃落定。
“Victoria C case ” in the Ministry of Commerce three “Court of Friends ” position was eventually adopted by the court of second instance, the principle of international comity prevail. However, this victory can not cover up the reality of the lack of legislation on the exemption of export cartels in China, the lack of precautionary measures in chambers of commerce, and the weak awareness of risk avoidance by enterprises. On September 20, 2016, the U.S. Federal Circuit Court of Appeals delivered its judgment on North China Pharmaceutical’s appeal against the “Vitamin C antitrust lawsuit” and supported the defendant’s motion that North China Pharmaceutical was rejected in the first instance. Based on the principle of international comity, The judgment of the first instance was invalid and the Chinese side won the verdict. So far, this protracted, known as the “first case of China’s international antitrust litigation,” the lawsuit finally settled.